Arsenal Bio Company Overview
Arsenal Biosciences (ArsenalBio) is a privately held biotechnology company focused on programmable cell therapies for cancer. The company engineers CRISPR-edited T cells with multiplex gene modifications and synthetic circuits to improve persistence, trafficking, and tumor killing in solid tumors. Its platform combines genome-scale screening, computational design, and in-house process development and manufacturing to create autologous CAR-T candidates with combinatorial edits. ArsenalBio is advancing clinical programs in solid tumors, including gynecologic cancers, and collaborates with academic and nonprofit partners such as the Parker Institute for Cancer Immunotherapy. Backed by leading life science investors, the company aims to extend the benefits of cellular immunotherapy beyond hematologic malignancies and address the challenges of treating solid tumors.
New to Pre-IPO Investing?
Get smarter about private markets and Pre-IPO investing:
- Get key practice tips for private-market investing
- Understand how to evaluate deal terms and common structures
- Evaluate fees and their impact on returns
- Develop a thesis and underwrite your investment
- Learn common pitfalls first-time investors face
FAQ
Does Arsenal Bio have stock?
Yes, Arsenal Bio and almost all privately held companies issue stock so founders, employees, and investors can participate in equity ownership. However, because Arsenal Bio is privately held, it is more challenging to acquire shares than if the company was publicly traded.
Is Arsenal Bio publicly traded?
No, Arsenal Bio is a privately held company. It is not publicly traded or offered directly on any stock exchange like the NYSE, Nasdaq, etc.
Who owns Arsenal Bio stock?
As a privately held company, Arsenal Bio shares are held by its founders, management, employees, venture
capital funds, or other private individuals and institutional investors.
Disclosure rules differ for private and public companies, so it may not always be possible to know the
complete ownership (cap table) of a private company like Arsenal Bio.
What is the stock symbol for Arsenal Bio?
Arsenal Bio is a privately held company. Therefore, it does not have a stock symbol or “ticker” that trades on public exchanges like the NYSE, Nasdaq, etc.
Can I buy Arsenal Bio shares on UpMarket?
If you would like to buy shares in Arsenal Bio, please provide your information in the form at the top of this page and click the button titled
“I want to buy this stock.”
One of our investor relations team members will contact you to discuss Arsenal Bio stock availability.
Note: inquiries are non-binding, subject to market availability, and shares may only be purchased by accredited investors that meet all
eligibility criteria.
UpMarket has offered many similar companies as Pre-IPO investments, including Airbnb, SpaceX, ByteDance,
Plaid, Kraken, Databricks, and others. UpMarket also often has funds available that invest in a portfolio of companies potentially including,
Arsenal Bio as well.
What is Arsenal Bio stock price?
The stock price of Arsenal Bio can be calculated by taking the valuation of the company divided by the number of shares outstanding. Because a private company can issue new shares at any time, we do not know the current number of shares outstanding.
How do Arsenal Bio pre-IPO trades work?
Pre-IPO trades for Arsenal Bio will typically involve accredited investors purchasing shares from current
shareholders through specialized investment platforms like UpMarket. Trades generally occur on the secondary market, meaning Arsenal Bio doesn't
issue new shares or receive capital–shares are privately exchanged between two parties.
While investors aim to profit from a potential IPO or acquisition, these investments carry high risks due to
limited liquidity and information. Understanding all terms and conditions is crucial, as each transaction can
have unique characteristics. Investing in private companies can be extremely risky and may result in
significant capital loss.
When is Arsenal Bio going to go public?
The decision to go public through an Initial Public Offering (IPO) is complex and depends on various factors,
including the company's financial performance, market conditions, and strategic goals.
Unless Arsenal Bio officially announces its intention to go public, any predictions about when or if it
will do so would be speculative.
Investors interested in Arsenal Bio should monitor official company communications and reliable financial
news sources for any updates regarding potential IPO plans.
How do I exit my investment if I invest in Arsenal Bio with UpMarket?
Exiting your investment in Arsenal Bio typically involves one of these scenarios: 1) selling your shares
on a secondary market to other interested investors; 2) holding shares until a liquidity event occurs, such as
the company going public (IPO) or being acquired.
Investors must know that the timing and availability of these exit options are inherently unpredictable, and
there is no guarantee of when or if they will occur.
How can I sell Arsenal Bio shares?
If you own Arsenal Bio shares, you may be able to find a buyer on a pre-IPO marketplace or via an introduction by a registered broker-dealer like UpMarket. It is important to note that the class of shares you own may impact your ability to sell. For example, shares issued to startup employees often have transaction limitations, including lock-up periods and a right of first refusal by the company, which may prevent you from selling your shares freely.
How does UpMarket estimate the valuation of Arsenal Bio?
UpMarket’s valuation estimate for Arsenal Bio is algorithmically generated based on recent primary round
financings by Arsenal Bio, market conditions, company popularity, sector performance, and public market
comps.
It is important to note that UpMarket’s valuation estimate for Arsenal Bio could be outdated, may not
reflect all recent news or market events, and is not intended to inform any investment decision-making.
UpMarket’s valuation estimate is not meant to be a warranty or projection of potential financial returns or
company performance. Valuations can change rapidly and unexpectedly.
Why choose UpMarket?
Founded in 2019, UpMarket has brokered over $1.3 billion in alternative investments for more than 1300+
investors, including principal invested and appreciation as of March 31, 2026. These investments span pre-IPO
companies, hedge funds, private equity, real estate, and other alternative assets. Approximately $301 million
is managed by UpMarket Management, with the remainder managed by affiliates. Past performance is not
predictive of future results. UpMarket is a licensed broker-dealer based in the United States.
If you are an accredited investor, you can create a
free account to access our deal flow and
opportunities. There is never any pressure to invest.
UpMarket clients have invested in companies like
Arsenal Bio,
Anduril, Perplexity, Neuralink, and many others. UpMarket and its leadership have been mentioned in media
outlets like Forbes,
WealthManagement,
Wealth
and Finance News, and TechBullion.
